Back to Search
Start Over
Curcumin prevents chronic intermittent hypoxia-induced myocardial injury
- Source :
- Therapeutic Advances in Chronic Disease, Vol 11 (2020), Therapeutic Advances in Chronic Disease, Therapeutic Advances in Chronic Disease, 2020, 11, pp.2040622320922104. ⟨10.1177/2040622320922104⟩
- Publication Year :
- 2020
- Publisher :
- SAGE Publications, 2020.
-
Abstract
- Background: Chronic intermittent hypoxia (IH), the hallmark feature of obstructive sleep apnoea syndrome, contributes to infarct size enhancement after myocardial ischemia–reperfusion (I/R). Curcumin (Curc), the natural pigment of Curcuma longa, has been demonstrated to be beneficial in the context of myocardial injury. In this study, we assessed the effects of Curc on the maladaptive cardiac response to IH, and particularly on IH-induced hypoxia inducible factor-1 (HIF-1) expression, oxidative stress, inflammation, endoplasmic reticulum (ER) stress and apoptosis. Methods: Swiss/SV129 mice were exposed to normoxia or IH (21–5% FiO2, 60 s cycles, 8 h per day, for 21 days) and treated orally with Curc (100 mg kg−1 day−1, oral gavage) or its vehicle. Mice were then either euthanised for heart sampling in order to perform biochemical and histological analysis, or subjected to an in vivo ischemia-reperfusion protocol in order to measure infarct size. Results: IH increased nuclear HIF-1α expression and superoxide anion (O2.–) production as well as nuclear factor kappa B (NF-kB) p65, glucose-regulated protein (Grp78) and C/EBP homologous protein (CHOP) expression. IH also induced apoptosis and increased infarct size after I/R . The IH-induced HIF-1 activation, oxidative stress, inflammation, ER stress and apoptosis were abolished by chronic Curc treatment. Curc also significantly decreased infarct size only in mice exposed to IH. Conclusion: Curc prevents IH-induced myocardial cell death signalling. Curc might be used as a combined therapy with continuous positive airway pressure in sleep apnoea patients with high cardiovascular risk.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
intermittent hypoxia
Medicine (miscellaneous)
030204 cardiovascular system & hematology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Chronic intermittent hypoxia
curcumin
myocardial injury
Obstructive sleep apnoea syndrome
Original Research
business.industry
lcsh:RM1-950
Intermittent hypoxia
Infarct size
[SDV] Life Sciences [q-bio]
lcsh:Therapeutics. Pharmacology
030104 developmental biology
chemistry
Cardiology
Curcumin
business
Subjects
Details
- ISSN :
- 20406231 and 20406223
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Chronic Disease
- Accession number :
- edsair.doi.dedup.....84b385a33ba0833fc72603c359f80202